Login / Signup

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

Dereje Abate NegatuRubén González Del RíoMónica CachoDavid Barros AguirreJoël LelievreJoaquín RullasPatricia CasadoUday S GanapathyMatthew D ZimmermanMartin GengenbacherVeronique Anne DartoisThomas Dick
Published in: Antimicrobial agents and chemotherapy (2023)
The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection. The results suggest that tebipenem-avibactam presents an attractive oral drug candidate pair for the treatment of M. abscessus pulmonary disease and could inform the design of clinical trials.
Keyphrases
  • gram negative
  • klebsiella pneumoniae
  • mouse model
  • multidrug resistant
  • clinical trial
  • escherichia coli
  • mycobacterium tuberculosis
  • pulmonary hypertension
  • emergency department
  • open label
  • adverse drug
  • double blind